Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD (continued)
Study
Description Intervention
Aman et al., 2005
McDougle et al.,
2005^
Arnold et al.,
2003†
RUPP, 2002‡
Williams et al,
2006º
Anderson et al.,
2007ª
Aman et al., 2008§
Martin et al.,
2004¥
(continued)
Inclusion/ Exclusion
Criteria/ Population
C-120
Baseline
Measures Outcomes
G1: 19.25 ± 11.4 VABS standard
(n=8)
score, post-
G2: 24.50 ± 10.5 extension phase,
(n=8)
mean change ±
Verbal learning task, SD:º
mean ± SD:§ Composite:
Immediate recall: G1: -0.29 ± 12.53
G1: 28.50 ± 11.9 (n=48)
(n=12)
G1/BL: P = NS
G2: 25.00 ± 8.8 (ES = -0.02)
(n=8)
Daily living skills:
Delayed recall: G1: 0.96 ± 10.35
G1: 6.20 ± 4.6 (n=48)
(n=12)
G1/BL: P = NS
G2: 4.67 ± 2.9 (n=8) (ES = 0.06)
Recognition: Medical:
G1: 77.87 ± 19.1 CYBOCS score,
(n=12)
post-RCT, mean ±
G2: 81.00 ± 11.6 SD:^
(n=8)
G1: 11.65 ± 4.02
G2: 14.21 ± 4.81
G1/G2: P = 0.005
(ES = 0.55)
Dot test, mean ± Weight increase,
SD:§
post-RCT, mean
Average distance: kg ± SD:‡
G1: 2.40 ± 1.0 (n=4) G1: 2.7 ± 2.9
G2: 3.52 ± 1.8 (n=4) G2: 0.8 ± 2.2
Average distance- G1/G2: P < 0.001
delay:
Weight increase,
G1: 7.19 ± 2.34 extension phase,
(n=4)
mean kg ± SD
G2: 4.95 ± 2.2 (n=4) (range):¥
Difference: G1: 5.6 ± 3.9 (-4.0
G1: 4.79 ± 2.0 (n=4) -15.3)
G2: 1.43 ± 1.5 (n=4) BMI, CDC
Harms:
standard score,
Potential harms, %: post-RCT, mean ±
Difficulty falling SD:
asleep:
G1: 1.0 ± 1.2
G1: 32.7
G2: 0.8 ± 1.3
G2: 50.0
G1/G2: P < 0.001
Tired during day: BMI increase,
G1: 14.3
G2: 23.1
extension phase,
mean kg/m
Enuresis:
G1: 40.8
G2: 32.7
Anxiety:
G1: 20.4
G2: 32.7
Rhinitis:
G1: 12.2
G2: 17.3
Excessive appetite:
G1: 12.2
G2: 11.5
2 ±
SD:¥
G1: 2.0 ± 1.9
SARS score, post-
RCT, mean ± SD:
G1: 0.52 ± 1.33
G2: 0.69 ± 2.48
G1/G2: P = NS
SARS score,
maximum value
during extension ±
SD:
G1: 0.71 ± 2.67